Yes, certain HLA types and expression levels can serve as prognostic biomarkers in cancer. For example, high expression of HLA Class I molecules in tumors is often associated with better prognosis and response to immunotherapy. Conversely, the loss or downregulation of HLA molecules can correlate with poor prognosis and resistance to treatment. Monitoring HLA expression and polymorphisms can provide valuable insights into the likely course of the disease and the most effective treatment options.
